BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28887309)

  • 1. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
    Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
    J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.
    Strittmatter BG; Jerde TJ; Hollenhorst PC
    PLoS Genet; 2021 Jul; 17(7):e1009708. PubMed ID: 34314419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
    Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
    Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells.
    Selvaraj N; Kedage V; Hollenhorst PC
    Cell Commun Signal; 2015 Feb; 13():12. PubMed ID: 25885538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
    Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
    Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
    Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
    J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
    Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
    Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
    Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
    Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
    Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
    J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
    Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
    Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
    Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F; Boutsalis G; Cartegni L
    PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
    Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
    Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations and deletions of PRC2 in prostate cancer.
    Jain P; Di Croce L
    Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
    Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
    Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.